T1	Entity 21 41	embryonic structures
T2	Entity 165 195	the serious medical conditions
T3	Entity 271 295	the efficient derivation
T4	Entity 409 442	the dual-SMAD inhibition strategy
T5	Entity 520 542	Concomitant inhibition
T6	Entity 621 637	surface ectoderm
T7	Entity 581 589	disrupts
T8	Entity 613 620	induces
T9	Cluster7 793 811	mature lens fibers
T10	Entity 870 885	transplantation
T11	Entity 947 954	in vivo
T12	Entity 919 946	adrenocorticotropic hormone
T13	Entity 669 689	the preplacode stage
T14	Entity 698 722	the selective generation
T15	Entity 726 760	placode-derived trigeminal ganglia
T16	Entity 1095 1121	human cell-based therapies
T17	Entity 1208 1221	BMP inhibitor
T18	Entity 1239 1245	induce
T19	Entity 1265 1270	hESCs
T20	Entity 978 1010	a powerful experimental platform
T21	Entity 1330 1347	epidermal lineage
T22	Entity 1322 1329	induces
T23	Entity 1294 1304	suppresses
T25	Entity 1421 1428	in vivo
T26	Cluster6 1413 1420	engraft
T27	Entity 1389 1399	functional
T28	Cluster8 1550 1565	the development
T29	Entity 1634 1658	the efficient derivation
T30	Entity 1782 1800	trigeminal ganglia
T31	Entity 1812 1819	in vivo
T32	Entity 1820 1831	engraftment
T33	Cluster8 1076 1091	the development
T34	Entity 1921 1928	in vivo
T35	Entity 2036 2055	placode derivatives
T36	Entity 2059 2080	regenerative medicine
T37	Entity 1954 1964	a platform
T38	Entity 1969 1977	studying
T39	Entity 2020 2032	applications
T40	Entity 1893 1902	producing
T41	Cluster1 0 16	Cranial placodes
T42	Entity 56 95	sensory and endocrine organ development
T43	Entity 97 122	Human placode development
T44	Cluster1 299 315	cranial placodes
T45	Cluster2 321 349	human pluripotent stem cells
T46	Entity 351 364	Timed removal
T47	Entity 368 392	the BMP inhibitor Noggin
T48	Entity 446 462	neural induction
T49	Entity 464 472	triggers
T50	Entity 473 490	placode induction
T51	Entity 509 518	CNS fates
T52	Entity 546 580	fibroblast growth factor signaling
T53	Entity 590 608	placode derivation
T54	Entity 647 665	fate specification
T55	Entity 817 859	anterior pituitary hormone-producing cells
T56	Entity 894 914	human growth hormone
T57	Cluster5 1020 1053	human cranial placode development
T58	Entity 1125 1154	sensory and endocrine disease
T59	Entity 1188 1204	Timed withdrawal
T60	Entity 1246 1259	placode fates
T61	Entity 1273 1293	Timed FGF inhibition
T62	Entity 1305 1317	placode fate
T63	Entity 1350 1384	Placode-derived trigeminal neurons
T64	Entity 1431 1462	Pituitary placode-derived cells
T65	Entity 1478 1493	hormone release
T66	Cluster1 1515 1531	Cranial placodes
T67	Entity 1569 1597	sensory and endocrine organs
T68	Cluster1 1662 1678	cranial placodes
T69	Cluster2 1684 1712	human pluripotent stem cells
T70	Cluster7 1833 1851	mature lens fibers
T71	Entity 1857 1881	anterior pituitary cells
T72	Entity 1903 1920	human GH and ACTH
T73	Cluster5 1978 2011	human cranial placode development
T74	Entity 206 221	the dysfunction
T75	Entity 225 248	placode-derived tissues
T76	Entity 772 779	in vivo
T77	Entity 780 791	engraftment
T78	Entity 1494 1514	in vitro and in vivo
T79	Entity 1745 1773	specific placode derivatives
T80	Cluster6 772 791	in vivo engraftment
T81	Cluster6 1812 1831	in vivo engraftment
T84	Cluster9 1714 1718	They
T85	Cluster9 1930 1935	Their
T24	Entity 1400 1408	in vitro
T82	Cluster4 978 1053	a powerful experimental platform to study human cranial placode development
T83	Cluster4 1954 2011	a platform for studying human cranial placode development
T86	Cluster10 1634 1678	the efficient derivation of cranial placodes
T87	Cluster10 271 315	the efficient derivation of cranial placodes
T88	Cluster11 256 258	we
T89	Cluster11 956 959	Our
